The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Zimelidine. The risk or severity of adverse effects can be increased when Amobarbital is combined with Tetracaine. The risk or severity of adverse effects can be increased when Tropicamide is combined with Dextropropoxyphene. The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxycodone. The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benzocaine. Minaprine may increase the hypotensive activities of Ramipril. The therapeutic efficacy of Glipizide can be decreased when used in combination with Cortisone acetate. The risk or severity of adverse effects can be increased when Ergotamine is combined with Mibefradil. Pivhydrazine may increase the hypotensive activities of Chlorothiazide. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ofloxacin. The serum concentration of Fluorouracil can be decreased when it is combined with Teriflunomide. The metabolism of Desvenlafaxine can be decreased when combined with Ketoconazole. The risk or severity of adverse effects can be increased when Propofol is combined with Meclizine. Miconazole may increase the hypoglycemic activities of Glyburide. The metabolism of Glipizide can be increased when combined with Pentobarbital. Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clozapine. Fosinopril may increase the hypotensive activities of Enalaprilat. Nicorandil may increase the hypotensive activities of Reserpine. Pirlindole may increase the hypoglycemic activities of Sulfisoxazole. Salmeterol may increase the hypokalemic activities of Polythiazide. The risk or severity of adverse effects can be increased when Benzydamine is combined with Clodronic Acid. The serum concentration of Ergoloid mesylate can be increased when it is combined with Cilazapril. The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prasterone. The risk or severity of adverse effects can be increased when Oxiconazole is combined with Pitavastatin. The serum concentration of Dapsone can be increased when it is combined with Simeprevir. The risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydrochlorothiazide. The serum concentration of Adapalene can be increased when it is combined with Probenecid. The metabolism of Finasteride can be decreased when combined with Atomoxetine. The serum concentration of Ciclesonide can be increased when it is combined with Estrone. The bioavailability of Cortisone acetate can be decreased when combined with Tromethamine. The risk or severity of adverse effects can be increased when Ondansetron is combined with Etidocaine. The metabolism of Pilocarpine can be decreased when combined with Saquinavir. The metabolism of Sibutramine can be decreased when combined with Clotrimazole. Diltiazem may increase the hypotensive activities of Cyclothiazide. The metabolism of Dasabuvir can be increased when combined with Phenobarbital. The risk or severity of adverse effects can be increased when Resveratrol is combined with Salicylamide. Tinoridine may increase the anticoagulant activities of Heparin. Norepinephrine may increase the atrioventricular blocking (AV block) activities of Nebivolol. The metabolism of Dasabuvir can be decreased when combined with Lumefantrine. The risk or severity of adverse effects can be increased when Valsartan is combined with Metolazone. The risk or severity of adverse effects can be increased when Zofenopril is combined with Duvelisib. The serum concentration of Afatinib can be increased when it is combined with Lidocaine. The risk or severity of adverse effects can be increased when Azelastine is combined with Indalpine. The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Sertindole. Ephedra may increase the hypokalemic activities of Trichlormethiazide. Carteolol may decrease the bronchodilatory activities of Phenylpropanolamine. The metabolism of Tolfenamic Acid can be increased when combined with Pentobarbital. The serum concentration of Amodiaquine can be increased when it is combined with Cyclosporine. The risk or severity of adverse effects can be increased when Propranolol is combined with Mannitol. Apomorphine may increase the atrioventricular blocking (AV block) activities of Bopindolol. The serum concentration of Dihydroergotamine can be increased when it is combined with Kitasamycin. The metabolism of Halothane can be increased when combined with Pentobarbital. Droperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine. The serum concentration of Rilpivirine can be increased when it is combined with Sertraline. The metabolism of Acetaminophen can be decreased when combined with Tipranavir. The metabolism of Levodopa can be decreased when combined with Desipramine. The risk or severity of adverse effects can be increased when Cilazapril is combined with Serrapeptase. Calcium Phosphate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. The serum concentration of Nebivolol can be increased when it is combined with Eliglustat. Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. The risk or severity of adverse effects can be increased when Baclofen is combined with Brompheniramine. The risk or severity of adverse effects can be increased when Sirolimus is combined with Zofenopril. The risk or severity of adverse effects can be increased when Enalapril is combined with Papaverine. Fluphenazine may increase the hypotensive activities of Pindolol. The serum concentration of Afatinib can be increased when it is combined with Azelastine. Amobarbital may increase the sedative activities of Ropinirole. The metabolism of Phenacetin can be decreased when combined with Dihydroergotamine. The metabolism of Aminophenazone can be increased when combined with Phenobarbital. The risk or severity of adverse effects can be increased when Bevantolol is combined with Cevimeline. The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Dienogest. The metabolism of Thalidomide can be decreased when combined with Sulfadiazine. The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydrocortisone. The risk or severity of adverse effects can be increased when Mizoribine is combined with Clobetasone. Phenylbutazone may increase the anticoagulant activities of Nafamostat. The risk or severity of adverse effects can be increased when Prasterone is combined with Physostigmine. The risk or severity of adverse effects can be increased when Amperozide is combined with Opium. Phentolamine may increase the hypotensive activities of Polythiazide. The risk or severity of adverse effects can be increased when Desoximetasone is combined with Prulifloxacin. The risk or severity of adverse effects can be increased when Brotizolam is combined with Clonidine. The risk or severity of adverse effects can be increased when Nicergoline is combined with Mefloquine. The metabolism of Gefitinib can be decreased when combined with Cocaine. The metabolism of Rivaroxaban can be decreased when combined with Ketoconazole. The serum concentration of Bupivacaine can be increased when it is combined with Pindolol. The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinolone Acetonide. The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Rofecoxib. The risk or severity of adverse effects can be increased when Rufinamide is combined with Doxylamine. The serum concentration of Ivacaftor can be increased when it is combined with Ziprasidone. Magnesium oxide may increase the neuromuscular blocking activities of Atracurium besylate. The metabolism of Dorzolamide can be decreased when combined with Clemastine. Pindolol may increase the hypotensive activities of Nitrendipine. Epinephrine may increase the atrioventricular blocking (AV block) activities of Timolol. The risk or severity of adverse effects can be increased when Propantheline is combined with Anisotropine Methylbromide. The risk or severity of adverse effects can be increased when Morphine is combined with Empagliflozin. The serum concentration of Amitriptyline can be increased when it is combined with Ramipril. The serum concentration of Rosuvastatin can be increased when it is combined with Ubenimex. Rilpivirine may increase the QTc-prolonging activities of Moxifloxacin. The metabolism of Orphenadrine can be decreased when combined with Cyclosporine. The risk or severity of adverse effects can be increased when Budesonide is combined with Trovafloxacin. The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methaqualone. The risk or severity of adverse effects can be increased when Atropine is combined with Dicyclomine. The metabolism of Deutetrabenazine can be decreased when combined with Artemether. Phenylpropanolamine may increase the hypokalemic activities of Etacrynic acid. The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Metolazone. Debrisoquin may increase the hypotensive activities of Indapamide. Flurandrenolide may decrease the antineoplastic activities of Aldesleukin. The risk or severity of adverse effects can be increased when Ketoprofen is combined with Formestane. The metabolism of Ergotamine can be decreased when combined with Isradipine. The metabolism of Carisoprodol can be decreased when combined with Ketoconazole. The risk or severity of adverse effects can be increased when Trandolapril is combined with Tenoxicam. Prazosin may increase the hypotensive activities of Vinpocetine. The serum concentration of Ergotamine can be increased when it is combined with Captopril. The metabolism of Methoxsalen can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Opium is combined with Bumetanide. The therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluocortolone. Nitroglycerin may increase the orthostatic hypotensive activities of Levodopa. The metabolism of Phenformin can be decreased when combined with Mirabegron. The metabolism of Trimethoprim can be decreased when combined with Sulfisoxazole. Zomepirac may decrease the antihypertensive activities of Penbutolol. The metabolism of Terfenadine can be decreased when combined with Artemether. The risk or severity of adverse effects can be increased when Timolol is combined with Bumetanide. Desipramine may decrease the antihypertensive activities of Clonidine. Fleroxacin may increase the hypoglycemic activities of Dapagliflozin. The risk or severity of adverse effects can be increased when Metolazone is combined with Clonidine. The therapeutic efficacy of Heparin can be decreased when used in combination with Norethisterone. The risk or severity of adverse effects can be increased when Salsalate is combined with Fluocinolone Acetonide. The serum concentration of Ubidecarenone can be increased when it is combined with Simeprevir. The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Azelastine. The serum concentration of Cyclosporine can be increased when it is combined with Aprotinin. The risk or severity of adverse effects can be increased when Antipyrine is combined with Salicylamide. The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Betamethasone.